Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy

Villatoro, Antonio J; Fernández, Viviana; Claros, Silvia; Alcoholado, Cristina; Cifuentes, Manuel; Merayo‐Lloves, Jesús; Andrades, José A.; Becerra, José

doi:10.3390/ijms18112264

Cited by 38 publications

(35 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DED is a complex and insidious pathology with a high level of prevalence among the human population [ 17 ]. Although the etiology of DED varies and the pathological mechanism is complicated, a common consensus is that the involvement of inflammation as an integral part of DED.…”

Section: Discussionmentioning

confidence: 99%

Tear Luminex Analysis in Dry Eye Patients

Zhao

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to analyze tear inflammatory cytokines of different subclasses of dry eye disease (DED) patients using Luminex technology.Material/MethodsForty-five DED patients including 20 Sjogren syndrome aqueous tear deficiency (SS-ATD) patients, 20 non-Sjogren syndrome aqueous tear deficiency (NSS-ATD) patients, 15 meibomian gland dysfunction (MGD) patients, and 15 normal participants were enrolled in this study. Concentrations of 11 inflammatory cytokines in tear samples of study participants were measured by Luminex assay; ELISA assay was further applied for validation.ResultsThe levels of cytokines were mostly increased (TNF-α, IL-1α, IL-1β, IL-6, IL-8, IL-12P70, IL-13, IFN-γ, and MIP-1α) in DED patients compared with normal participants. And the levels of TNF-α, IL-6, IL-8, and IL-12P70 were significantly elevated in tears of the patient groups compared to tears of participants in the normal group (P<0.05). Statistical differences were also observed among the patient groups (SS-ATD, NSS-ATD, and MGD) for the level of IL-8 and TNF-α. The results of ELISA assay demonstrated the consistence with Luminex assay, confirming the practicality of Luminex technology for the analysis of multiple cytokines in DED patient tears.ConclusionsThe levels of inflammatory cytokines were mostly elevated in DED patients, and statistical differences of some cytokines were also found between SS-ATD, NSS-ATD, and MGD groups, suggesting that inflammatory cytokines could be potential supplements for the diagnosis of DED subclasses and therapeutic targets for DED patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Tear Luminex Analysis in Dry Eye Patients

Zhao

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Dry eye syndrome has multiple comorbidities (see Box 3; Villatoro et al, 2017). Menopause, diabetes, the use of antihistamines, and laser surgery are all contributing factors to the development of dry eyes.…”

Section: Risk Factorsmentioning

confidence: 99%

Menopause and Dry Eye Syndrome

Lurati¹

2019

Nursing for Women's Health

View full text Add to dashboard Cite

“…MSCs express low levels of major histocompatibility complex class I (MHC-I) but lack expression of MHC-II surface molecules. Their low immunogenicity and their immunomodulatory potential allow their allogeneic use, which makes them a promising new treatment for severe refractory autoimmune diseases [28,[33][34][35][36][37].…”

Section: Allogeneic Vs Autologous Mscs Usementioning

confidence: 99%

New Approaches to Dermatological Conditions Employing Mesenchymal Stem Cell Therapies

Prieto¹

2018

CDOAJ

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are multipotent stem cells with the capacity to differentiate in vitro into diverse cell lineages and secrete different bioactive molecules with trophic, paracrine and immunomodulatory functions. On the other hand, skin inflammation may be a sign of allergic, autoimmune, or infectious conditions and it is observed in several diseases such as atopic dermatitis, cutaneous graft versus host disease, cutaneous lupus erythematosus, psoriasis and systemic sclerosis. Traditional therapies for these skin diseases are not completely effective and have potential systemic adverse events. Consequently, new safer therapies need to be developed, being MSCs a value alternative. Due to the lack of knowledge on MSCs mode of action, animal models of disease help to discern their mechanism of immunoregulation and improve their safety after their application. The literature supports that MSCs act by a paracrine via by using anti-inflammatory cytokines targeting specifically those cells involved in the inflammation of immune-regulated diseases. Consequently, MSCs reduce the excessive immune responses and protect the adjacent tissues.

show abstract

Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy

Cited by 38 publications

References 98 publications

Tear Luminex Analysis in Dry Eye Patients

Tear Luminex Analysis in Dry Eye Patients

Menopause and Dry Eye Syndrome

New Approaches to Dermatological Conditions Employing Mesenchymal Stem Cell Therapies

Contact Info

Product

Resources

About